Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors
Advances in Medical Sciences · 2024-09 · 69 (2) · 407-415
DOI: 10.1016/j.advms.2024.09.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Medical Sciences, 2024-09. Verfasst von Grzegorz Procyk und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw, Poland. …. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as a new name for the previous non-alcoholic fatty liver disease (NAFLD). There are some differences between MASLD and NAFLD, e.g., diagnostic criteria. MASLD is a hepatic steatosis without harmful alcohol consumption and is caused by metabolic factors. The prevalence of MASLD varies amongst different populations. The change in lifestyle plays a fundamental role in MASLD management, while there is no registered pharmacotherapy in this indication. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been suggested to have a beneficial effect on hepatic steatosis, hence, they have been widely investigated as potential therapeutics in MASLD. In this review, we aimed to thoroughly summarize current evidence from original research about the effects of SGLT2i use on MASLD. Almost all discussed studies advocate using SGLT2i in MASLD because of their beneficial effects. It includes the loss of body weight, which is beneficial per se, and the improvement in hepatic parameters. Most importantly, steatosis reduction has been observed in patients using SGLT2i. We highly recommend further research in this field, which we believe will eventually lead to a new indication for SGLT2i, i.e., MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw, Poland. Electronic address: grzegorz.procyk@wum.edu.pl.
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
- Institute of Clinical Science, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland; Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.
- Cardiovascular Diseases Department, University Hospital of Split, Split, Croatia.
Zitieren
APA
Procyk, G., Jaworski, J., Gąsecka, A., Filipiak, K. J., & Borovac, J. A. (2024). Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors. Advances in Medical Sciences, 69(2), 407-415. https://doi.org/10.1016/j.advms.2024.09.001
Vancouver
Procyk G, Jaworski J, Gąsecka A, Filipiak KJ, Borovac JA. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors. Advances in Medical Sciences. 2024;69(2):407-415. doi:10.1016/j.advms.2024.09.001
BibTeX
@article{Procyk2024,
author = {Procyk, Grzegorz and Jaworski, Jakub and Gąsecka, Aleksandra and Filipiak, Krzysztof J and Borovac, Josip A},
title = {Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors},
journal = {Advances in Medical Sciences},
year = {2024},
volume = {69},
number = {2},
pages = {407--415},
doi = {10.1016/j.advms.2024.09.001}
}
EUVIMED